Alnylam Pharmace. buy William Blair
Start price
19.11.24
/
50%
€221.30
Target price
19.11.25
-
Performance (%)
80.48%
End price
20.11.25
€399.40
Summary
This prediction ended on 20.11.25 with a price of €399.40. The BUY prediction by William_Blair for Alnylam Pharmace. saw massive gains of 80.48%. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 6.498% | 6.498% | -1.582% |
| iShares Core DAX® | 4,37 % | 4,83 % | 8,17 % |
| iShares Nasdaq 100 | -0,29 % | 3,31 % | 34,82 % |
| iShares Nikkei 225® | -0,47 % | 8,53 % | 62,39 % |
| iShares S&P 500 | 1,27 % | 2,86 % | 25,64 % |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten